I gained a degree in Pharmacy and a PhD in Pharmaceutical Chemistry and Microbiology from the University of Nottingham and then spent 5 years as a postdoc at the University of Leicester exploring the enzymology of DNA processing enzymes, routinely designing new higher throughput enzyme and cell-based assays. I joined the CRUK (then ICRF) translational drug discovery lab in 1999, ostensibly to design HTS assays, but spent the next 20 years building and managing extensive HTS, assay sciences, structural biology and protein sciences teams. In my final 6 years at CRUK, now Deputy Director of Drug Discovery, I was focussed on negotiating and running “at-scale” multi-project Academia-Industry collaborations. I was the CRUK lead on the 5-year DUB alliance which successfully discovered a number of new inhibitors of deubiquitinase enzymes as potential anticancer therapeutics. With accumulated experience in the collaborative DUB drug discovery space, I was delighted to join Entact Bio as VP Drug Discovery at its formation in stealth mode in 2019. Over the next 2 years we subsequently built the ENTAC platform and portfolio and following the successful funding round I stepped into a consultancy role. I continue to thoroughly enjoy working closely with the Entact Bio leadership team.
See what Tim and their colleagues have been up to:
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Guiding a young, groundbreaking company to maturity calls for a leader who can strike the right balance between oversight and support. Victoria Richon is hoping to provide just that as the new CEO of Entact Bio, a preclinical biotech that came out of stealth in December...
Entact Bio: Victoria Richon, CEO
The language of drug development is often militaristic. Medicinal chemists build arsenals of small molecules—looking for inhibitors or “warheads” that can hit “targets” and “combat” disease. Block, eliminate, disrupt, halt. For decades, drug makers have sought “magic bullets” that can precisely destroy ...
Entact Bio launches with $81 million to enhance protein function
When proteins within the body get tagged with a molecule called ubiquitin, they are essentially marked for destruction. But they can be saved; a deubiquitinase enzyme can remove the ubiquitin, keeping the protein intact. That, at least in part, is what Entact Bio aims to do...
Biotech cofounded by Dana-Farber scientists launches with $81m for new approach to drugs
A small startup in Watertown has raised millions of dollars for early-stage research on a potentially powerful new idea that’s beginning to take hold in the biotech industry: designing drugs to enhance or prolong the function of helpful proteins that ward off disease. If successful, the approach could lead to new therapie...